{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:35:11Z","timestamp":1788910511414,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejpb.2023.02.012","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T09:30:43Z","timestamp":1677231043000},"page":"137-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Improved drug transfer into brain tissue via the \u201cnose-to-brain\u201d approach using suspension or powder formulations based on the amorphous solid dispersion technique"],"prefix":"10.1016","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-6214","authenticated-orcid":false,"given":"Susumu","family":"Suwabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4488-2127","authenticated-orcid":false,"given":"Tetsuya","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.02.012_b0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0010","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0015","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/1061186X.2019.1574300","article-title":"Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease","volume":"27","author":"Tiozzo","year":"2019","journal-title":"J. Drug Targeting"},{"key":"10.1016\/j.ejpb.2023.02.012_b0020","article-title":"Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation","volume":"605","author":"Fasiolo","year":"2021","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-5173(01)00736-0","article-title":"Improved nasal bioavailability of elcatonin by insoluble powder formulation","volume":"224","author":"Ishikawa","year":"2001","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0030","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1023\/A:1019881706159","article-title":"Insoluble powder formulation as an effective nasal drug delivery system","volume":"19","author":"Ishikawa","year":"2002","journal-title":"Pharm Res."},{"key":"10.1016\/j.ejpb.2023.02.012_b0035","doi-asserted-by":"crossref","first-page":"e0159150","DOI":"10.1371\/journal.pone.0159150","article-title":"Nasal absorption of macromolecules from powder formulations and effects of sodium carboxymethyl cellulose on their absorption","volume":"11","author":"Tanaka","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.02.012_b0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejps.2017.09.027","article-title":"Opportunity and challenges of nasal powders: Drug formulation and delivery","volume":"113","author":"Fasiolo","year":"2018","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics13030385","article-title":"Nasal powder formulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects","volume":"13","author":"Trenkel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.02.012_b0050","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/jps.2600600902","article-title":"Pharmaceutical applications of solid dispersion systems","volume":"60","author":"Chiou","year":"1971","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejpb.2013.09.007","article-title":"Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs","volume":"85","author":"Vo","year":"2013","journal-title":"Eur J Pharm Biopharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0060","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jps.24541","article-title":"Amorphous solid dispersions: Utilization and challenges in drug discovery and development","volume":"104","author":"He","year":"2015","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2015.12.010","article-title":"Spray drying formulation of amorphous solid dispersions","volume":"100","author":"Singh","year":"2016","journal-title":"Adv Drug Delivery Rev."},{"key":"10.1016\/j.ejpb.2023.02.012_b0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1208\/s12249-018-1280-0","article-title":"Spray-dried pulmoSphere\u2122 formulations for inhalation comprising crystalline drug particles","volume":"20","author":"Weers","year":"2019","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2023.02.012_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/2231-4040.107496","article-title":"In vitro dissolution study of atorvastatin binary solid dispersion","volume":"4","author":"Jahan","year":"2013","journal-title":"J Adv Pharm Technol Res."},{"key":"10.1016\/j.ejpb.2023.02.012_b0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0378-5173(81)90058-2","article-title":"Absorption of drugs from the nasal mucosa of rat","volume":"7","author":"Hirai","year":"1981","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejps.2016.09.028","article-title":"Nasal drug absorption from powder formulations: The effect of three types of hydroxypropyl cellulose (HPC)","volume":"96","author":"Tanaka","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0095","first-page":"72","article-title":"Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain","volume":"13","author":"Liu","year":"2018","journal-title":"Asian J Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0731-7085(00)00262-4","article-title":"Solid-state study of polymorphic drugs: carbamazepine","volume":"23","author":"Rustichelli","year":"2000","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ejpb.2023.02.012_b0105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jsps.2018.02.017","article-title":"Development of ternary solid dispersions with hydrophilic polymer and surface adsorbent for improving dissolution rate of carbamazepine","volume":"26","author":"Vojinovi\u0107","year":"2018","journal-title":"Saudi Pharm J."},{"key":"10.1016\/j.ejpb.2023.02.012_b0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.powtec.2011.09.041","article-title":"Microstructured ternary solid dispersions to improve carbamazepine solubility","volume":"215","author":"Martins","year":"2012","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2023.02.012_b0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-5173(99)00315-4","article-title":"Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate","volume":"193","author":"Kobayashi","year":"2000","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0120","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/jps.22541","article-title":"Prediction of the thermal phase diagram of amorphous solid dispersions by Flory-Huggins theory","volume":"100","author":"Zhao","year":"2011","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejps.2017.05.013","article-title":"Evaluation of a biphasic in vitro dissolution test for estimating the bioavailability of carbamazepine polymorphic forms","volume":"105","author":"Deng","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.ejpb.2023.02.012_b0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2016.08.008","article-title":"Solid dispersions of efonidipine hydrochloride ethanolate with improved physicochemical and pharmacokinetic properties prepared with microwave treatment","volume":"108","author":"Otsuka","year":"2016","journal-title":"Eur J Pharm Biopharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0135","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2174\/138920112803341752","article-title":"Drug delivery systems from nose to brain","volume":"13","author":"Misra","year":"2012","journal-title":"Curr Pharm Biotechnol."},{"key":"10.1016\/j.ejpb.2023.02.012_b0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1081\/DDC-100101266","article-title":"A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations","volume":"26","author":"Khan","year":"2000","journal-title":"Drug Dev Ind Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10837450802282462","article-title":"Preparation and evaluation of piroxicam-HPMCAS solid dispersions for ocular use","volume":"13","author":"Jachowicz","year":"2008","journal-title":"Pharm Dev Technol."},{"key":"10.1016\/j.ejpb.2023.02.012_b0150","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/pharmaceutics12070625","article-title":"Unraveling particle formation: from single droplet drying to spray drying and electrospraying","volume":"12","author":"Boel","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.02.012_b0155","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/03639045.2017.1411941","article-title":"Brain-targeted intranasal zaleplon solid dispersion in hydrophilic carrier system; 23 full-factorial design and in vivo determination of GABA neurotransmitter","volume":"44","author":"Abd-Elrasheed","year":"2018","journal-title":"Drug Dev Ind Pharm."},{"key":"10.1016\/j.ejpb.2023.02.012_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2019.101401","article-title":"An effective polyvinyl alcohol for the solubilization of poorly water-soluble drugs in solid dispersion formulations","volume":"55","author":"Umemoto","year":"2020","journal-title":"J Drug Delivery Sci Technol."},{"key":"10.1016\/j.ejpb.2023.02.012_b0165","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/03639045.2011.587428","article-title":"The use of spray-drying to enhance celecoxib solubility","volume":"37","author":"Fouad","year":"2011","journal-title":"Drug Dev Ind Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:51:10Z","timestamp":1760547070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"alternative-id":["S0939641123000504"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.012","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved drug transfer into brain tissue via the \u201cnose-to-brain\u201d approach using suspension or powder formulations based on the amorphous solid dispersion technique","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}